Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Canada Defeats Neupogen Patent Claims On Obviousness

Company Now Holds NOC For Nivestym Filgrastim Biosimilar

Executive Summary

With a biosimilar to Amgen’s Neupogen already on the market in the US, Pfizer has challenged key claims of Amgen’s Canadian drug substance patent, in an attempt to clear a path to market for its Nivestym biosimilar.

You may also be interested in...

Sandoz’ Ziextenzo And Riximyo Cleared In Canada

Sandoz Canada is looking to bolster its portfolio of biosimilars after obtaining marketing authorizations for both pegfilgrastim and rituximab.

Canadian Originators Are Free To Try Again

Samsung Bioepis Added To Avastin Biosimilar Litigants

Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts